Business Context and Reporting Period
This Form 8-K Current Report was filed by BeiGene, Ltd. on January 10, 2022, covering events occurring on January 6, 2022. The registrant is a Cayman Islands-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines for the treatment of cancer. The report details regulatory approvals and reimbursement listings in China effective January 1, 2022.
Key Financial Metrics
This filing is a current report regarding regulatory events and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Regulatory Events
The filing reports two primary material events regarding the Company's commercialization in China:
- National Reimbursement Drug List (NRDL) Inclusion: Three medicines were included in the updated NRDL effective January 1, 2022, with specific payment standards set by the National Healthcare Security Administration (NHSA):
- Tislelizumab: Included for all five approved indications. The payment standard is RMB 1,450 per 100mg vial. Three new indications were added in this cycle (NSCLC non-squamous, Hepatocellular Carcinoma, and NSCLC squamous).
- BRUKINSA (zanubrutinib): Included for all three approved indications. The payment standard is RMB 85 per 80mg capsule. One new indication was added (Waldenström's macroglobulinemia).
- Pamiparib: Included for its approved indication in gBRCA mutation-associated recurrent advanced ovarian cancer. The payment standard is RMB 53.60 per 20mg capsule.
- New Regulatory Approval: The China National Medical Products Administration (NMPA) approved tislelizumab as a second- or third-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Guidance, Outlook, and Risks
The filing does not provide forward-looking financial guidance, management commentary on future performance, or a discussion of risks and contingencies. The document strictly reports the inclusion of medicines in the NRDL and the NMPA approval of a new indication for tislelizumab.
Investor Verification Checklist
- Verify the commercial impact of the NRDL payment standards (RMB 1,450 for tislelizumab, RMB 85 for BRUKINSA, RMB 53.60 for pamiparib) on future revenue projections in China.
- Confirm the specific patient populations covered by the three new tislelizumab indications added to the NRDL.
- Review the attached press release (Exhibit 99.1) for details on the NMPA approval of tislelizumab for second- or third-line NSCLC treatment.
- Check subsequent filings for financial results to assess the actual revenue contribution from these newly reimbursed indications.